Cite
HARVARD Citation
Han, B. et al. (n.d.). 134P Safety and efficacy of multi-target TKI combined with nivolumab in checkpoint inhibitor-refractory advanced NSCLC patients: A prospective, single arm, two stage study. Immuno-oncology technology. p. . [Online].